Uncertainties and Anxieties about Vaccination, Answering Parent's Concerns

Journal of Pediatric Nursing

Volumn 24, Issue 5, 2009, Pages 433-440

  Purssell, Edward ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Immunization; Immunogenicity; Infection; Safety; Vaccination

Indexed keywords

ANAPHYLAXIS; ANXIETY; ARTICLE; ATTITUDE TO HEALTH; COMPENSATION; EDUCATION; HEALTH EDUCATION; HUMAN; IMMUNIZATION; NURSE ATTITUDE; NURSING; ORGANIZATION AND MANAGEMENT; PARENT; PREVENTIVE HEALTH SERVICE; PSYCHOLOGICAL ASPECT; SAFETY; STATISTICS; UNCERTAINTY; VACCINATION;

ANAPHYLAXIS; ANXIETY; ATTITUDE TO HEALTH; COMPENSATION AND REDRESS; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; NURSE'S ROLE; PARENTS; SAFETY; UNCERTAINTY; VACCINATION;

EID: 70349301385     PISSN: 08825963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pedn.2009.03.002     Document Type: Article

References (44)

1. Anderson R.M. Infectious diseases of humans (1991), Oxford University Press, Oxford
2. Baker J.P. The pertussis vaccine controversy in Great Britain, 1974-1986. Vaccine 21 (2003) 4003-4010
3. Bellaby P. Communication and miscommunication of risk: Understanding UK parents' attitudes to combined MMR vaccination. BMJ 327 (2003) 725-728
4. Bohlke K., Davis R.L., Marcy S.M., Braun M.M., DeStefano F., Black S.B., et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 112 (2003) 815-820
5. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: Addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 21 (2002) 298-302
6. Bradford Hill A. The environment and disease: Association or causation?. Proceedings of the Royal Society of Medicine 58 (1965) 295-300
7. Carrat F., and Flahault A. Influenza vaccine: The challenge of antigenic drift. Vaccine 25 (2007) 6852-6862
8. CDC. Epidemiology and prevention of vaccine-preventable diseases. 10th ed. (2008), Public Health Foundation, Washington, DC
9. DoH. Immunisation against infectious diseases (2006), Department of Health, London
10. Drummond M., Chevat C., and Lothgren M. Do we fully understand the economic value of vaccines?. Vaccine 25 (2007) 5945-5957
11. Evans G. Vaccine injury compensation programs worldwide. Vaccine 17 Supplement 3 (1999) S25-S35
12. FDA. Guidance for industry for the evaluation of combination vaccines for preventable diseases: Production, testing and clinical studies (1997), Food and Drug Administration, Rockville, MD
13. Freed G.L. Lessons from across the pond: What the US can learn from European immunization programs. Vaccine 25 (2007) 6148-6157
14. Halsey N.A. Combination vaccines: Defining and addressing current safety concerns. Clinical Infectious Diseases 33 s4 (2001) S312-S318
15. Halsey N.A. The science of evaluation of adverse events associated with vaccination. Seminars in Pediatric Infectious Diseases 13 (2002) 205-214
16. Haynes B. Can it work? Does it work? Is it worth it?. BMJ 319 (1999) 652-653
17. Hilton S., Petticrew M., and Hunt K. 'Combined vaccines are like a sudden onslaught to the body's immune system': Parental concerns about vaccine 'overload' and 'immune-vulnerability'. Vaccine 24 (2006) 4321-4327
18. Hudgens M.G., Gilbert P.B., and Self S.G. Endpoints in vaccine trials. Statistical Methods in Medical Research 13 (2004) 89-114
19. Isaacs D. Should Australia introduce a vaccine injury compensation scheme?. Journal of Paediatrics and Child Health 40 (2004) 247-249
20. Jacobson R.M., and Poland G.A. The genetic basis for measles vaccine failure. Acta Paediatrica 93 s445 (2004) 43-46
21. Khakoo G.A., and Lack G. Recommendations for using MMR vaccine in children allergic to eggs. British Medical Journal 320 (2000) 929-932
22. Ladhani S., Slack M.P., Heys M., White J., and Ramsay M.E. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Archives of Disease in Childhood 93 (2008) 665-669
23. Lucas R.N., and McMichael A.J. Association or causation: Evaluating links between "environment and disease". Bulletin of the World Health Organisation 83 (2005) 792-795
24. McBrien J., Murphy J., Gill D., Cronin M., O'Donovan C., and Cafferkey M.T. Measles outbreak in Dublin, 2000. Pediatric Infectious Disease Journal 22 (2003) 580-584
25. Murch S.H., Anthony A., Casson D.H., Malik M., Berelowitz M., Dhillon A.P., et al. Retraction of an interpretation. Lancet 363 (2004) 750
26. Offit P.A., and Jew R.K. Addressing parents' concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals?. Pediatrics 112 (2003) 1394-1397
27. Offit P.A., and Moser C.A. The problem with Dr Bob's alternative vaccine schedule. Pediatrics 123 (2009) e164-e169
28. Offit P.A., Quarles J., Gerber M.A., Hackett C.J., Marcuse E.K., Kollman T.R., et al. Addressing parents' concerns: Do multiple vaccines overwhelm or weaken the infant's immune system?. Pediatrics 109 (2002) 124-129
29. Parker S.K., Schwartz B., Todd J., and Pickering L.K. Thimerosal-containing vaccines and autistic spectrum disorder: A critical review of published original data. Pediatrics 114 (2004) 793-804
30. Petousis-Harris H. Vaccine injection technique and reactogenicity-Evidence for practice. Vaccine 26 (2008) 6299-6304
31. Pichichero M.E., Cernichiari E., Lopreiato J., and Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: A descriptive study. Lancet 360 (2002) 1737-1741
32. Plotkin S.A. Vaccines: Correlates of vaccine-induced immunity. Clinical Infectious Diseases 47 (2008) 401-409
33. Rennels M.B. The rotavirus vaccine story: A clinical investigator's view. Pediatrics 106 (2000) 123-125
34. Sengupta N., Booy R., Schmitt H., Peltola H., Van-Damme P., Schumacher R., et al. Varicella vaccination in Europe: Are we ready for a universal childhood programme?. European Journal of Pediatrics 167 (2008) 47-55
35. Siegrist C.-A. Neonatal and early life vaccinology. Vaccine 19 (2001) 3331-3346
36. Smeeth L., Rodrigues L.C., Hall A.J., Fombonne E., and Smith P.G. Evaluation of adverse effects of vaccines: The case-control approach. Vaccine 20 (2002) 2611-2617
37. Tapiainen T., Cherry J.D., and Heininger U. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine 23 (2005) 5106-5112
38. Tozzi A.E. Field evaluation of vaccine safety. Vaccine 22 (2004) 2091-2095
39. Vidor E. The nature and consequences of intra- and inter-vaccine interference. Journal of Comparative Pathology 137 Supplement 1 (2007) S62-S66
40. Wakefield A.J., Murch S.H., Anthony A., Linnell J., Casson D.M., Malik M., et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351 (1998) 637-641
41. WHO. Operational targets for EPI diseases (1996), WHO Regional Office for Europe, Copenhagen
42. WHO. State of the world's vaccines and immunization (2003), World Health Organization, Geneva
43. WHO. Guidelines on clinical evaluation of vaccines: Regulatory expectations. Fifty-second report. Annexe 1 (2004), World Health Organization, Geneva
44. WHO. Guidelines on nonclinical evaluation of vaccines WHO Technical Report Series No. 927, Annex 1 (2005), World Health Organisation, Geneva